GA NCORP
Sign Up for Newsletter

newsletter archive

 Jun 21, 2017

GA NCORP Research Connections - Volume 3 Spring 2017

Note from the PIs This year we are off to another exciting start for the GA NCORP network that follows on the heels of an extraordinarily accomplished 2016. In late 2016, TMIST was approved for funding, and the trial is expected to open mid-2017. The NCI-MATCH screening trial (EAY131), closed in May of this year and SWOG S1404 will be closing summer 2017 with first data to be analyzed in the fall. GA NCORP is continuing with immunotherapy NCI initiative and continues to accrue patients for the E1609 and EA6141 trials. GA NCORP’s current portfolio comprises 83 clinical trials that are active and accruing. In the first and second years combined, NCORP at the national level accrued 7,527 patients to NCORP trials (including enrollment to quality-of-life sub-studies for treatment trials); and 6,742 patients were accrued to NCTN trials. We have also observed positive trends in investigator participation and accruals. The number of rostered investigators accruing at least one patient to an

http://files.constantcontact.com/68d5d6bf401/187a7455-dd12-405b-b2f6-f1c76f575d3c.pdf?ver=1497299037000

 Mar 28, 2016

Georgia NCORP Research Connections - Volume 2 - Winter 2016

Note from the PIs This year is off to an exciting start for the Georgia NCORP network, and follows on the heels of an extraordinarily accomplished 2015. In early February 2016, we were informed that our application for SWOG membership was approved. Membership with SWOG will provide Georgia NCORP investigators and patients expanded access to clinical trials and cancer care delivery studies, as well as opportunities to contribute to the development of studies through committee and group meeting participation. Membership in SWOG is a great honor and will enhance GA NCORP’s members’ ability to provide patients the very best in clinical research opportunities.

http://files.ctctcdn.com/68d5d6bf401/2734f599-27bc-4ab2-8921-933085536344.pdf

 May 01, 2015

Research Connections Volume 1

In this issue you will learn about the NCORP program, the aims of the GA NCORP initiative, and the achievements to date of our efforts. Highlights of the five NCI high-priority trials for patients with lung and breast cancers, solid tumors and lymphoma, and patients who have been exceptional responders in previous NCI clinical trials are reviewed. Should you have any patients who would benefit from access to these trials, please contact the GA NCORP site principal investigator closest to you for more information.

http://files.ctctcdn.com/68d5d6bf401/6c3f4de3-c36b-4ff5-8987-f71e5de15034.pdf